

RNS Number : 3751N
Intl. Biotechnology Trust PLC
17 January 2019

INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)

Portfolio Update as at 31 December 2018

Net Assets	£209m
Net Assets per share	556p
Share price	570p
Total value of unquoted investments	£30m
Total number of portfolio companies	61
Dividend	4% of NAV per annum

Top Ten Quoted Investments

Company Name	% NAV
Incyte	6.1
Vertex	5.6
Celgene	5.4
Genmab	5.1
Gilead Sciences	5.0
Regeneron	4.4
Exelixis	4.4
Illumina	3.8
Neurocrine	3.4
Biomarin	3.0

	-
Total	46.2

Geographical Allocation	% NAV
US & Canada	87
Europe	13

	-
Total	100

Quoted/Unquoted Allocation	% NAV
Quoted	85
Unquoted	15

	-
Total	100

NAV % Market Cap	% NAV
Large Cap >USD10BN	44
Mid Cap =USD1-10BN	33
Small Cap <USD1BN	23

	-
Total	100

NAV % by Therapeutic Areas	% NAV
Oncology	35
Rare diseases	21
CNS	10
Ophthalmology	5
Infectious Diseases	5
Tools	4
Inflammation	3
Medtech	3
Metabolic	0
Other	14

	-
Total	100

BNP Paribas Secretarial Services Limited

Company Secretary

17 JANUARY 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PFUGIGDBIUBBGCR

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

Portfolio Update - RNS